ESMO 2025

Oncology

ESMO 2025 reflected a field in the midst of rapid evolution – one that is increasingly defined by personalisation and data-driven decision-making.

Oncology

At ESMO 2025, pharmaphorum spoke with Dr Ebrahim Delpassand, CEO of RadioMedix.

Oncology

At ESMO 2025, pharmaphorum had the pleasure of speaking with Michael Lahn, Chief Medical Officer at iOnctura.

Oncology

At ESMO 2025 in Berlin, pharmaphorum spoke with Jo Feng, president of Hengrui Pharma.

Oncology

As ESMO 2025 came to a close last month, pharmaphorum had the pleasure of catching up with Dr Sandeep Reddy, Chief Medical Officer at ImmunityBio.

Oncology

At ESMO 2025 in Berlin, pharmaphorum spoke with Tadaaki Taniguchi, Chief Research & Development Officer at Astellas.